It has been found that 177Lu-based treatments yield significant positive results in treating gastroenteropancreatic neuroendocrine tumors (GEP-NET), including pancreatic neuroendocrine tumors that express somatostatin receptors (SSTR) and patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC). The gene discussed is FOLH1; the disease is digestive system neuroendocrine tumor, grade 1/2.